Updates from the EMBRACA trial for advanced breast cancer

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer

Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC

Comment on the Every Woman Study

Therapeutic targeting at a pre-metastatic stage for brain metastases from lung cancer

Recent advances in CNS tumour management

Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer

Updates in head and neck cancers

KEYNOTE022: Triplet therapy for BRAF melanoma

First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

SPLENDOUR: Added denosumab in first line adv NSCLC treatment